IL-36γ Drives Skin Toxicity Induced by EGFR/MEK Inhibition and Commensal Cutibacterium Acnes

    Takashi Satoh, Mark Mellett, Barbara Meier‐Schiesser, Gabriele Fenini, Atsushi Otsuka, Hans‐Dietmar Beer, Tamara Rordorf, Julia-Tatjana Maul, Jürg Hafner, Alexander A. Navarini, Emmanuel Contassot, Lars E. French
    Studysummary This study found that EGFR and MEK inhibitors may induce acneiform skin toxicities by interacting with the skin bacterium Cutibacterium acnes to increase IL-36γ and IL-8 production in keratinocytes.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    In 2020, researchers discovered that the inflammatory molecule IL-36γ, in conjunction with the skin bacterium Cutibacterium acnes, was a significant factor in skin toxicity caused by EGFR/MEK inhibitors, a treatment for various cancers. The study found that these inhibitors, along with Cutibacterium acnes, induced the production of IL-36γ in keratinocytes, leading to skin inflammation and hair loss. The transcription factor KLF4 was identified as a key regulator of IL-36γ transcriptional activity in response to EGFR inhibition. The study also revealed that the mouse IL-36γ promoter lacks the KLF4 binding site found in humans, suggesting that mice may not be an appropriate model for studying EGFRi-induced acneiform skin toxicity. The findings suggested that IL-36γ and KLF4 could be potential therapeutic targets for managing skin toxicities caused by EGFRi/MEKi. The number of participants in the study was not mentioned.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results